02851nas a2200217   4500008004100000245013500041210006900176260000800245300000900253490000700262520199000269653002202259653004302281653003902324653003502363653002902398100002102427700002702448700003002475856012802505       2023                        eng d00aIsolation and molecular characterization of indigenous penicillium chrysogenum/rubens strain portfolio for penicillin V production0 aIsolation and molecular characterization of indigenous penicilli  cAPR  a11320 v113 a<p>
	Beta (beta)-lactam antibiotic is an industrially important molecule produced by Penicillium chrysogenum/rubens. Penicillin is a building block for 6-aminopenicillanic acid (6-APA), an important active pharmaceutical intermediate (API) used for semi-synthetic antibiotics biosynthesis. In this investigation, we isolated and identified Penicillium chrysogenum, P. rubens, P. brocae, P. citrinum, Aspergillus fumigatus, A. sydowii, Talaromyces tratensis, Scopulariopsis brevicaulis, P. oxalicum, and P. dipodomyicola using the internal transcribed spacer (ITS) region and the beta-tubulin (BenA) gene for precise species identification from Indian origin. Furthermore, the BenA gene distinguished between complex species of P. chrysogenum and P. rubens to a certain extent which partially failed by the ITS region. In addition, these species were distinguished by metabolic markers profiled by liquid chromatography-high resolution mass spectrometry (LC-HRMS). Secalonic acid, Meleagrin, and Roquefortine C were absent in P. rubens. The crude extract evaluated for PenV production by antibacterial activities by well diffusion method against Staphylococcus aureus NCIM-2079. A high-performance liquid chromatography (HPLC) method was developed for simultaneous detection of 6-APA, phenoxymethyl penicillin (PenV), and phenoxyacetic acid (POA). The pivotal objective was the development of an indigenous strain portfolio for PenV production. Here, a library of 80 strains of P. chrysogenum/rubens was screened for PenV production. Results showed 28 strains capable of producing PenV in a range from 10 to 120 mg/L when 80 strains were screened for its production. In addition, fermentation parameters, precursor concentration, incubation period, inoculum size, pH, and temperature were monitored for the improved PenV production using promising P. rubens strain BIONCL P45. In conclusion, P. chrysogenum/rubens strains can be explored for the industrial-scale PenV production.</p>
10abeta-tubulin gene10ahigh-performance liquid chromatography10ainternal transcribed spacer region10aPenicillium chrysogenum/rubens10aphenoxymethyl penicillin1 aSawant, Amol, M.1 aNavale, Vishwambar, D.1 aVamkudoth, Koteswara, Rao  uhttps://library.ncl.res.in/content/isolation-and-molecular-characterization-indigenous-penicillium-chrysogenumrubens-strain02994nas a2200301   4500008004100000022001400041245017000055210006900225260000800294300001100302490000800313520193900321653001802260653001602278653001502294653001602309653001802325653002402343100002302367700001902390700002502409700002202434700003002456700002102486700002702507700002702534856013102561       2025                        eng d  a0882-401000aAn integrated paradigm to understand the antibacterial and antifungal potential of bimetallic core-shell platinum silver (Pt@Ag) nanoparticles: A one health approach0 aintegrated paradigm to understand the antibacterial and antifung  cDEC  a1081200 v2093 a<p>
	The concurrent occurrence of various microbial infections escalates the need to develop new treatments that can tackle multiple microbes and improve clinical outcomes. This study reports the synthesis and comprehensive evaluation of core-shell platinum-silver nanoparticles (Pt@AgNPs) designed to elucidate the antimicrobial effects while ensuring biocompatibility. The synthesis protocol was meticulously optimized to investigate the impact of precursor concentrations and reagent conditions. High-end characterization confirmed the formation of a welldefined core-shell structure with spherical morphology, crystalline nature, a face-centred cubic (FCC) lattice, high monodispersity, and stability, with a mean size of 20.344 +/- 4.492 nm. The antimicrobial potential of Pt@AgNPs was validated through a minimum inhibitory concentration (MIC) assay, revealing potent activity with MIC values of 15.6 mu g/mL for Pseudomonas aeruginosa and Staphylococcus aureus and 3.9 mu g/mL for Escherichia coli. Antibiofilm assay demonstrated significant inhibition of biofilm formation by P. aeruginosa at concentrations as low as 3.9 mu g/ml. The nanoparticles also exhibited notable antifungal activity, as indicated by an inhibition of 65.19 % for Aspergillus niger and 61.82 % for Fusarium verticillioides. Furthermore, hemocompatibility was noticed with the hemolysis assay, and the antioxidant properties of nanoparticles, assessed through the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay, underscored their potential to mitigate oxidative stress. This integrative study positions Pt@AgNPs as a promising platform for combating the occurrence of co-infections. The core-shell nanoparticle serves as a versatile tool in antimicrobial defence, exhibiting antibacterial, antifungal, antibiofilm, and antioxidant activity. Thus, it highlights their commercial translational potential as a next-generation antimicrobial intervention.</p>
10aAntibacterial10aantibiofilm10aantifungal10aAntioxidant10aCo-infections10aPt@Ag nanoparticles1 aBamb, Aagam, Lalit1 aVarma, Sanjana1 aGade, Tejas, Subhash1 aPalaskar, Shahaji1 aVamkudoth, Koteswara, Rao1 aVyawahare, Niraj1 aChaudhari, Pallavi, M.1 aChaudhari, Bhushan, P.  uhttps://library.ncl.res.in/content/integrated-paradigm-understand-antibacterial-and-antifungal-potential-bimetallic-core-shell